Unknown

Dataset Information

0

Antimicrobial activity of the investigational pleuromutilin compound BC-3781 tested against Gram-positive organisms commonly associated with acute bacterial skin and skin structure infections.


ABSTRACT: BC-3781 is a novel semisynthetic pleuromutilin antimicrobial agent developed as an intravenous and oral therapy for acute bacterial skin and skin structure infections (ABSSSI) and respiratory tract infections (RTI). BC-3781 and comparator agents were tested by the broth microdilution method against 1,893 clinical Gram-positive organisms predominantly causing ABSSSI. BC-3781 exhibited potent activity against methicillin-resistant Staphylococcus aureus (MIC(50/90), 0.12/0.25 ?g/ml), coagulase-negative staphylococci (MIC(50/90), 0.06/0.12 ?g/ml), ?-hemolytic streptococci (MIC(50/90), 0.03/0.06 ?g/ml), viridans group streptococci (MIC(50/90), 0.12/0.5 ?g/ml), and Enterococcus faecium (including vancomycin-nonsusceptible strains) (MIC(50/90), 0.12/2 ?g/ml). Compared with other antibiotics in use for the treatment of ABSSSI, BC-3781 displayed the lowest MICs and only a minimal potential for cross-resistance with other antimicrobial classes.

SUBMITTER: Sader HS 

PROVIDER: S-EPMC3294907 | biostudies-literature | 2012 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Antimicrobial activity of the investigational pleuromutilin compound BC-3781 tested against Gram-positive organisms commonly associated with acute bacterial skin and skin structure infections.

Sader Helio S HS   Biedenbach Douglas J DJ   Paukner Susanne S   Ivezic-Schoenfeld Zrinka Z   Jones Ronald N RN  

Antimicrobial agents and chemotherapy 20120109 3


BC-3781 is a novel semisynthetic pleuromutilin antimicrobial agent developed as an intravenous and oral therapy for acute bacterial skin and skin structure infections (ABSSSI) and respiratory tract infections (RTI). BC-3781 and comparator agents were tested by the broth microdilution method against 1,893 clinical Gram-positive organisms predominantly causing ABSSSI. BC-3781 exhibited potent activity against methicillin-resistant Staphylococcus aureus (MIC(50/90), 0.12/0.25 μg/ml), coagulase-nega  ...[more]

Similar Datasets

| PRJNA377578 | ENA
2014-05-30 | GSE57245 | GEO
2014-05-30 | E-GEOD-57245 | biostudies-arrayexpress
| S-EPMC3957905 | biostudies-literature
| S-EPMC5154188 | biostudies-literature
2008-02-26 | GSE7163 | GEO
2010-05-26 | E-GEOD-7163 | biostudies-arrayexpress
2021-04-29 | GSE162168 | GEO
| S-EPMC3228624 | biostudies-literature
| S-EPMC8750248 | biostudies-literature